Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals 'superhero DNA'
DNA
The findings could be a starting point from which to investigate other changes or anomalies in developing therapies.
Research reveals genetic disease resilience
 
An international team of researchers have studied a database of nearly 600,000 people revealing that 13 were born with ‘superhero DNA’.  

Published in Nature Biotechnology, the approach reveals that 13 healthy people should have developed one of eight severe genetic diseases. The next step is to unravel why.

In a pioneering approach to genetic studies, the focus was directed at the DNA of those who remain healthy, rather than those who became ill. The findings could be a starting point from which to investigate other changes or anomalies in developing therapies.

In an interview with the BBC, Dr Eric Schadt from the Icahn School of Medicine at Mount Sinai Hospital in New York, said: “Most genomic studies focus on finding the cause of a disease, but we see tremendous opportunity in figuring out what keeps people healthy.”

However, progress with the findings has been limited by consent rules signed by the database of DNA sample providers. Despite discovering 13 ‘genetic superheroes’, the scientists are unable to trace them. Pulling into question the ethics behind genetic data sharing, the study is an example of what can be achieved through anonymous genetic and clinical data.

Talking to the BBC, Dr Matthew Hurles, from the Wellcome Trust Sanger Institute, said: “The full benefits of such altruistic data sharing is only fully realised when it becomes possible to go back to the resilient individual to try and understand how their resilience is achieved.”

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.